ProKidney Corp. (NASDAQ:PROK) Receives $6.25 Consensus Price Target from Brokerages

Key Points

• ProKidney Corp. has received a consensus rating of "Hold" from five analysts, with one sell, one hold, and three buy recommendations.
• The average 12-month price target for ProKidney's shares is $6.25, while different analysts have set individual targets ranging from $1.00 to $9.00.
• ProKidney reported an earnings per share (EPS) of (0.13) for the last quarter, beating analysts' expectations by $0.03.

ProKidney Corp. (NASDAQ:PROK - Get Free Report) has received a consensus recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $6.25.

A number of equities analysts have recently weighed in on the company. Guggenheim reiterated a "buy" rating and set a $7.00 target price (up previously from $6.00) on shares of ProKidney in a research note on Monday, July 14th. UBS Group raised their target price on ProKidney from $4.00 to $8.00 and gave the stock a "buy" rating in a research report on Tuesday, July 15th. Citigroup reissued a "buy" rating and issued a $9.00 price objective (up from $6.00) on shares of ProKidney in a research report on Wednesday, July 9th. Bank of America downgraded ProKidney from a "neutral" rating to an "underperform" rating and reduced their target price for the company from $3.00 to $1.00 in a research note on Monday, June 30th. Finally, Wall Street Zen upgraded ProKidney from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd.

Insider Transactions at ProKidney

In other ProKidney news, insider Darin J. Weber sold 103,480 shares of the business's stock in a transaction on Tuesday, July 8th. The shares were sold at an average price of $3.02, for a total transaction of $312,509.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 41.49% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. ProShare Advisors LLC increased its stake in ProKidney by 57.3% in the fourth quarter. ProShare Advisors LLC now owns 30,879 shares of the company's stock valued at $52,000 after acquiring an additional 11,250 shares during the last quarter. Sei Investments Co. bought a new position in shares of ProKidney during the fourth quarter valued at approximately $69,000. Susquehanna Fundamental Investments LLC bought a new position in shares of ProKidney during the fourth quarter valued at approximately $88,000. AQR Capital Management LLC increased its position in shares of ProKidney by 106.4% during the first quarter. AQR Capital Management LLC now owns 52,570 shares of the company's stock valued at $46,000 after acquiring an additional 27,098 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of ProKidney by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 54,098 shares of the company's stock valued at $91,000 after acquiring an additional 18,431 shares in the last quarter. 51.59% of the stock is currently owned by hedge funds and other institutional investors.

ProKidney Stock Up 0.2%

PROK traded up $0.01 during trading on Friday, hitting $2.27. The company's stock had a trading volume of 1,410,227 shares, compared to its average volume of 5,849,307. The firm's 50 day moving average price is $2.02 and its two-hundred day moving average price is $1.37. ProKidney has a 12 month low of $0.46 and a 12 month high of $7.13. The stock has a market capitalization of $662.97 million, a price-to-earnings ratio of -3.81 and a beta of 1.76.

ProKidney (NASDAQ:PROK - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.16) by $0.03. The business had revenue of $0.23 million during the quarter. On average, sell-side analysts forecast that ProKidney will post -0.57 earnings per share for the current year.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.